Latest Shareholder Approvals News

Next Science Limited has applied for voluntary delisting from the ASX following the sale of nearly all its assets to OSARTIS GmbH. The company proposes a capital return to shareholders and intends to commence winding up after delisting.

Next Science has obtained a crucial ASX waiver allowing it to return surplus capital to shareholders following its $50 million asset sale, despite expected share price declines below 20 cents.

The Supreme Court of New South Wales has approved Southern Cross Media's acquisition of Seven West Media, setting the stage for a significant media industry consolidation early next year.

Wingara AG Limited has arranged a $250,000 unsecured loan facility from NAOS Asset Management entities, featuring a convertible note option that could reshape its capital structure.

Scorpion Minerals has executed a binding option agreement to acquire the Old Prospect tenements within its Pharos Gold Project, adding a JORC-compliant resource of over 21,600 ounces of gold. The acquisition consolidates tenure along a highly prospective 5km structural corridor in Western Australia’s Murchison region.

American Tungsten & Antimony Ltd plans to unlock value by spinning out its Drummond Basin and NSW gold exploration assets into a new ASX-listed company, King Metals Limited, aiming to raise up to $6 million in an IPO.

Chimeric Therapeutics has raised $8.4 million to fully fund its lead CHM CDH17 CAR-T Phase 1/2 trial through Phase 1, while initiating a strategic reset to sharpen focus and reduce costs.

Metgasco has pushed back the deadline for Vintage Energy’s commitment to acquire its stake in the Odin and Vali Gas Fields, extending the timeline while keeping the overall transaction completion date intact.

Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.

Neurizon Therapeutics has locked in a $44 million funding package to fully support its lead drug NUZ-001 in the HEALEY ALS Platform Trial, marking a critical step toward potential regulatory approval and broader neurodegenerative applications.

OZZ Resources has entered a binding option agreement with Scorpion Minerals, offering an exclusive chance to acquire its key tenements for $2.6 million plus a gold production royalty. The deal awaits shareholder approval and hinges on several regulatory and operational conditions.

Rox Resources has completed a $200 million capital raise, including a $134 million second tranche placement, to fund development of its Youanmi Gold Project in Western Australia.